The drugmaker attributes the forecasted revenue and adjusted earnings to a strong demand for its recently launched diabetes and psoriasis drugs. In addition, the company expects additional progress in its drug portfolio in 2018, including a new rheumatoid arthritis treatment.
Even though Eli Lilly has seen increased competition from biosimilars entering the market, the company reaffirmed its expectation of at least a 5 percent annual revenue growth rate from 2015 to 2020.
More articles on supply chain:
10 recent pharma layoffs
Sanofi urges Philippine government to lift suspension of its dengue vaccine
Medline to relocate supply distribution center in Maryland, triple its workforce
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
